Journal of insurance medicine (New York, N.Y.)最新文献

筛选
英文 中文
GitHub and Google Colab for Sharing Data and Code. GitHub和谷歌Colab共享数据和代码。
Journal of insurance medicine (New York, N.Y.) Pub Date : 2026-06-15 DOI: 10.17849/insm-53-2-1-4.1A
David Wesley
{"title":"GitHub and Google Colab for Sharing Data and Code.","authors":"David Wesley","doi":"10.17849/insm-53-2-1-4.1A","DOIUrl":"10.17849/insm-53-2-1-4.1A","url":null,"abstract":"<p><p>A traditional print journal is not ideal for the dissemination of computer code and related data. Without the actual code and data, reproducibility cannot be assessed, and there can be no validation of the premise of such an article. Fortunately, there are inexpensive modern ways to share both data and code while providing for explanatory text: GitHub and Google Colaboratory. This article introduces both and provides 3 different examples for the reader to experience.</p>","PeriodicalId":39345,"journal":{"name":"Journal of insurance medicine (New York, N.Y.)","volume":"53 2","pages":"199-202"},"PeriodicalIF":0.0,"publicationDate":"2026-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148266465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
When Is a Test "Genetic?" The Case of Multi-Cancer Early Detection Tests. 什么时候测试是“遗传的”?多癌早期检测试验案例
Journal of insurance medicine (New York, N.Y.) Pub Date : 2026-06-15 DOI: 10.17849/insm-53-2-1-4.1B
Timothy Meagher
{"title":"When Is a Test \"Genetic?\" The Case of Multi-Cancer Early Detection Tests.","authors":"Timothy Meagher","doi":"10.17849/insm-53-2-1-4.1B","DOIUrl":"10.17849/insm-53-2-1-4.1B","url":null,"abstract":"<p><p>Multi-cancer early detection (MCED) tests are increasingly popular. Are these tests \"genetic,\" and if so, can insurers use them in the risk assessment process? This article reviews definitions of genetic tests. It then reviews the motivation for limiting insurers' access to genetic tests and examines the wording in the legislation in 3 English speaking jurisdictions. It then attempts to establish whether MECD results are included in the legislation.</p>","PeriodicalId":39345,"journal":{"name":"Journal of insurance medicine (New York, N.Y.)","volume":"53 2","pages":"217-220"},"PeriodicalIF":0.0,"publicationDate":"2026-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148266523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Coronary Artery Calcium Score - Practical Considerations for Underwriting. 冠状动脉钙评分-承保的实际考虑。
Journal of insurance medicine (New York, N.Y.) Pub Date : 2026-06-15 DOI: 10.17849/insm-53-2-1-7.1A
Emoke Posan
{"title":"Coronary Artery Calcium Score - Practical Considerations for Underwriting.","authors":"Emoke Posan","doi":"10.17849/insm-53-2-1-7.1A","DOIUrl":"10.17849/insm-53-2-1-7.1A","url":null,"abstract":"<p><p>This brief practical review explores the fundamentals of coronary artery calcium score testing, its role in cardiovascular risk stratification, and how it can empower underwriting CV risks with greater clarity, speed, and confidence.</p>","PeriodicalId":39345,"journal":{"name":"Journal of insurance medicine (New York, N.Y.)","volume":"53 2","pages":"192-198"},"PeriodicalIF":0.0,"publicationDate":"2026-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148266445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Creating Evidence-Based Ratings and Life Expectancies Medical Impairments. 创建基于证据的评分和预期寿命医疗损伤。
Journal of insurance medicine (New York, N.Y.) Pub Date : 2026-06-15 DOI: 10.17849/insm-53-2-1-4.1
John R Iacovino
{"title":"Creating Evidence-Based Ratings and Life Expectancies Medical Impairments.","authors":"John R Iacovino","doi":"10.17849/insm-53-2-1-4.1","DOIUrl":"10.17849/insm-53-2-1-4.1","url":null,"abstract":"<p><p>Accurate and profitable risk selection requires evidence-based survival information. Medical Impairment Manual (MIM) ratings and life expectancies can be determined from illustrated survival and/or mortality curves in the medical literature. This article illustrates how to utilize these curves to calculate MIM ratings and life expectancy estimations.</p>","PeriodicalId":39345,"journal":{"name":"Journal of insurance medicine (New York, N.Y.)","volume":"53 2","pages":"124-127"},"PeriodicalIF":0.0,"publicationDate":"2026-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148266451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Smoking Dilemma: A Technical Deep Dive. 吸烟的困境:技术上的深入研究。
Journal of insurance medicine (New York, N.Y.) Pub Date : 2026-06-15 DOI: 10.17849/insm-53-2-1-13.1
Natalia Reyes-Cancino, Elyssa Del Valle, Asha Sapre, José Chedid
{"title":"The Smoking Dilemma: A Technical Deep Dive.","authors":"Natalia Reyes-Cancino, Elyssa Del Valle, Asha Sapre, José Chedid","doi":"10.17849/insm-53-2-1-13.1","DOIUrl":"10.17849/insm-53-2-1-13.1","url":null,"abstract":"<p><p>Traditional cigarette smoking has declined markedly over recent decades due to increased health awareness, regulatory action, and public health campaigns. At the same time, alternative nicotine products, particularly e-cigarettes and oral nicotine pouches, have gained popularity, especially in the United States and Europe and among younger populations. While cigarettes remain the most widely used tobacco product globally, tobacco and nicotine consumption now spans a broad range of combustible and non-combustible products, with smokeless tobacco predominating in some regions. Definitions of a \"smoker\" vary significantly between clinical practice and insurance medicine. Clinical definitions are nuanced and health-focused, whereas insurance classifications are typically binary and time-bound, often defining a smoker as anyone who has used a nicotine-containing product within the past 12 months. The growing use of alternative nicotine products, alongside evolving cannabis legislation, has exposed limitations in traditional definitions when it comes to accurately capturing associated risk. The expansion of alternative nicotine products challenges traditional smoker classifications used in insurance underwriting. While combustible tobacco remains the highest risk exposure, growing evidence supports the existence of a heterogeneous medium risk group associated with nicotine, noncombustible products. Although generally lower risk than cigarettes, these products are not risk-free, particularly considering early cardiovascular and metabolic effects, dual or poly-use patterns, and growing uptake at younger ages. For insurers, this evolving landscape highlights the benefit of a more nuanced underwriting approach, including enhanced disclosure of product type and use patterns, improved verification strategies, and potential pricing differentiation that better aligns risk with exposure.</p>","PeriodicalId":39345,"journal":{"name":"Journal of insurance medicine (New York, N.Y.)","volume":"53 2","pages":"135-147"},"PeriodicalIF":0.0,"publicationDate":"2026-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148266468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Problems Using Body Mass Index (BMI) to Assess Mortality. 使用身体质量指数(BMI)评估死亡率的问题。
Journal of insurance medicine (New York, N.Y.) Pub Date : 2026-06-15 DOI: 10.17849/insm-53-2-1-5.1A
Rodney C Richie
{"title":"Problems Using Body Mass Index (BMI) to Assess Mortality.","authors":"Rodney C Richie","doi":"10.17849/insm-53-2-1-5.1A","DOIUrl":"10.17849/insm-53-2-1-5.1A","url":null,"abstract":"<p><p>There is increasing unease in the medical community about using the predictive value of the body measurement index (BMI) as a guide to an individual's current and future health. Elevated BMIs are evaluated by life and disability underwriters as part of a comprehensive review, but other than verifying overweight status, the predictive value of BMI on future morbidity and mortality is questionable until the BMI is >35, and several studies have shown better mortality in the \"overweight\" BMI 25-29.9 category than in the \"normal\" BMI 18.5-24.9 category. The goal of this treatise is to evaluate other anthropomorphic measurements that might be better predictors of future health.</p>","PeriodicalId":39345,"journal":{"name":"Journal of insurance medicine (New York, N.Y.)","volume":"53 2","pages":"187-191"},"PeriodicalIF":0.0,"publicationDate":"2026-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148266492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prostate Cancer - 20-Year Comparative Mortality and Survival Analysis by Age, Race/Ethnicity, Stage, Grade, Disease Duration and Cohort Entry Period: A Systematic Review of 648,114 cases for Diagnosis Years 1975-2022. 前列腺癌——按年龄、种族/民族、分期、分级、病程和队列进入期划分的20年死亡率和生存率比较分析:1975-2022年诊断年份648114例病例的系统回顾
Journal of insurance medicine (New York, N.Y.) Pub Date : 2026-06-15 DOI: 10.17849/insm-53-2-1-34.1
Anthony F Milano
{"title":"Prostate Cancer - 20-Year Comparative Mortality and Survival Analysis by Age, Race/Ethnicity, Stage, Grade, Disease Duration and Cohort Entry Period: A Systematic Review of 648,114 cases for Diagnosis Years 1975-2022.","authors":"Anthony F Milano","doi":"10.17849/insm-53-2-1-34.1","DOIUrl":"10.17849/insm-53-2-1-34.1","url":null,"abstract":"<p><p>Prostate cancer is a major cause of disease and mortality among older men (mean age 67.3 years old) in the United States and globally. Given the biological heterogeneity of this cancer in this short- and long-term United States retrospective population-based analysis, the focus is on incidence, mortality, and survival by age, race/ethnicity, stage, and severity in cohort entry time periods (1975-99 and 2000-22), and disease duration. This comparative cohort short- and long-term study is intended to provide age-adjusted epidemiologic and demographic survival and mortality data for convenient reference by all physicians, scientists, insurance underwriters, and others interested in cancer mortality follow-up.</p>","PeriodicalId":39345,"journal":{"name":"Journal of insurance medicine (New York, N.Y.)","volume":"53 2","pages":"148-181"},"PeriodicalIF":0.0,"publicationDate":"2026-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148266470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hazard Ratio to Life Expectancy: Gompertz-Makeham Validation of Emerging Risk Factors Collaboration Cardiometabolic Multimorbidity Tables. 预期寿命的风险比:Gompertz-Makeham对新出现的危险因素协作的心脏代谢多病表的验证。
Journal of insurance medicine (New York, N.Y.) Pub Date : 2026-06-15 DOI: 10.17849/insm-53-2-1-7.1B
Bernard Silke
{"title":"Hazard Ratio to Life Expectancy: Gompertz-Makeham Validation of Emerging Risk Factors Collaboration Cardiometabolic Multimorbidity Tables.","authors":"Bernard Silke","doi":"10.17849/insm-53-2-1-7.1B","DOIUrl":"10.17849/insm-53-2-1-7.1B","url":null,"abstract":"<p><strong>Objective.—: </strong>To validate Emerging Risk Factors Collaboration (ERFC) high-risk cardiometabolic life years lost (LYL) tables using Gompertz-Makeham calibrated to hazard ratios, offering a reproducible framework for insurance underwriting and medico-legal life expectancy projections.</p><p><strong>Methods.—: </strong>ERFC LYL tables (91 cohorts; 689,300 participants; HR≥5) benchmarked against Irish Life Tables No. 17 via constant HR∼9.5 multiplier. Gompertz-Makeham generated risk-group survival curves; LYL as baseline-risk differential ages 40-85. Model performance via mean absolute error (MAE).</p><p><strong>Results.—: </strong>Gompertz-Makeham reproduced ERFC high-risk LYL (males MAE 1.21 years; females 1.16 years across 40-85), preserving empirical S-curve without disease-specific adjustments (Table 2; Figures 1-3). Age 40 loses, 20-22 years; age 75, 5-6 years.</p><p><strong>Conclusions.—: </strong>HR-calibrated Gompertz-Makeham provides aetiology-independent LYL estimates within 1 - 2 years mean absolute error (MAE), extending Strauss/Shavelle disability models to multimorbidity for actuarial risk assessment and forensic reports.</p>","PeriodicalId":39345,"journal":{"name":"Journal of insurance medicine (New York, N.Y.)","volume":"53 2","pages":"203-209"},"PeriodicalIF":0.0,"publicationDate":"2026-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148266421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Disability Risk for Male Professional Soccer Players: A Question of Age? A New Method Based on Transfermarkt®'s Collaborative Data. 男性职业足球运动员的残疾风险:年龄的问题?基于Transfermarkt®协同数据的新方法。
Journal of insurance medicine (New York, N.Y.) Pub Date : 2026-06-15 DOI: 10.17849/insm-53-2-1-7.1C
Antoine Moll, Denis Charles, Zeynep Kaya, Manuel Plisson, Julien Tomas, Irene Merk, Viet Chi Tran, Thierry Jeantheau, Pierre Sabouret
{"title":"Disability Risk for Male Professional Soccer Players: A Question of Age? A New Method Based on Transfermarkt®'s Collaborative Data.","authors":"Antoine Moll, Denis Charles, Zeynep Kaya, Manuel Plisson, Julien Tomas, Irene Merk, Viet Chi Tran, Thierry Jeantheau, Pierre Sabouret","doi":"10.17849/insm-53-2-1-7.1C","DOIUrl":"10.17849/insm-53-2-1-7.1C","url":null,"abstract":"<p><p>The soccer industry generates billions in revenue, largely from matchday sales, commercial activities, and television rights. A significant portion of club revenues are spent on player wages making their availability for games and training economically vital. Any period of injury-related absence functions as a form of temporary disability, creating significant financial exposure for teams, insurers, and reinsurers. Preventing injuries is crucial for soccer clubs to mitigate financial and sports risks associated with player unavailability. Transfermarkt® database has been utilized to develop an accurate method to estimate the incidence of injuries among male soccer players. To propose the most appropriate preventive measures, medical teams of soccer clubs should consider other risk factors than age, such as the history of injuries and the player's position in the field. This new model offers a practical framework for insurers, reinsurers, and club medical teams to better quantify disability risk, refine prevention strategies, and improve the prediction of injury-related downtime.</p>","PeriodicalId":39345,"journal":{"name":"Journal of insurance medicine (New York, N.Y.)","volume":"53 2","pages":"210-216"},"PeriodicalIF":0.0,"publicationDate":"2026-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148266461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
GLP-1 Therapies and Mortality Risk: Implications for Life Insurers. GLP-1治疗和死亡风险:对寿险公司的启示。
Journal of insurance medicine (New York, N.Y.) Pub Date : 2026-06-15 DOI: 10.17849/insm-53-2-1-7.1
Gina C Guzman, Tristan Walsh
{"title":"GLP-1 Therapies and Mortality Risk: Implications for Life Insurers.","authors":"Gina C Guzman, Tristan Walsh","doi":"10.17849/insm-53-2-1-7.1","DOIUrl":"10.17849/insm-53-2-1-7.1","url":null,"abstract":"<p><p>Glucagon-like peptide-1 (GLP-1) receptor agonists have rapidly expanded beyond their initial role in diabetes management, demonstrating therapeutic potential across a range of non-diabetic conditions. Due to their potential to improve mortality and morbidity outcomes, GLP-1 drugs are becoming an increasingly salient topic for insurers, particularly in relation to mortality improvement, medical underwriting, and new product development. Our large-scale mortality study estimates that GLP-1 drugs may drive 0.2%-0.5% annual mortality improvement, realized over a 20-year period. Low adherence could limit long-term mortality benefits, and electronic health records will be vital for accurately assessing metabolic risk in underwriting. The mortality benefits identified for GLP-1 drugs present opportunities for carriers to transform how they assess metabolic risk in underwriting programs. However, variation in individual risk profiles, driven by poor adherence and inconsistent behavioral change, as well as other factors, underscores the need for nuance in program design and application.</p>","PeriodicalId":39345,"journal":{"name":"Journal of insurance medicine (New York, N.Y.)","volume":"53 2","pages":"128-134"},"PeriodicalIF":0.0,"publicationDate":"2026-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148266477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书